TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| OVP participates in Complete Genomics $45 million round OVP Venture Partners continues to invest in large financing deals in companies located outside the Seattle area. The latest for the Kirkland venture firm is Complete Genomics, a Mountain View, Calif.-based company that Monday announced $45 million in new funding. feeds.bizjournals.com |
Stroke’s No Joke - Video AD COUNCIL AND AMERICAN STROKE ASSOCIATION LAUNCH NEW PSAs TO ENCOURAGE AFRICAN AMERICANS TO RESPOND EARLY TO STROKE SYMPTOMS feedproxy.google.com |
5 Biotech Stocks to Keep an Eye On Oncolytics Biotech, Inc. (NASDAQ:ONCY) makes our list of stocks to watch after reaching an agreement with the U.S. Food and Drug Administration under the special protocol assessment process for the design of a Phase 3 trial examining REOLYSIN in head and neck cancers.On Friday, Oncolytics said it's the first company to reach an agreement with the FDA on a Phase 3 trial design for an IV-administered oncolytic virus under the SPA process. The SPA is an agreement between Oncolytics and the FDA that the design and planned analyses of the Phase 3 study is adequately designed to provide the necessary data. The stock traded above it's 52-week high on Friday, but shares ticked down a bit after hours. As news spreads about this key development, interest in the company may rise as well since a license application submission for REOLYSIN would become a major development for the Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.Complete Story » seekingalpha.com |
EXACT Sciences: Patience Required for Long-Term Upside Mike Havrilla submits:On 11/3/09, EXACT Sciences (NASDAQ: EXAS) reported its 3Q09 results and held a conference call to outline the Company’s progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer (CRC). EXAS reported total revenue of $1.3 million (which primarily reflects non-cash recognition of Genzyme deal earlier this year), a net loss of $1 million, operating expenses of $2.3 million, and ended the quarter with cash / equivalents of $26.9 million.Last week, EXAS made a SEC 8-K filing regarding its President / CEO, Kevin T. Conroy, who is considering a run for Governor of Wisconsin in 2010. Mr. Conroy stated on the call today that a succession plan is premature at this point, and he plans to make a decision in the very near future on whether to make the run for governor (this would be communicated in the form of another SEC 8-K filing) – indicating that he is only considering such a move because of confidence in the strong team that is already in place at EXAS.Complete Story » seekingalpha.com |
Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition (PR Newswire) A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA. us.rd.yahoo.com |